-- Friday, October 5, 2007; 12:30 - 2:00 p.m. in Poster Halls G-H.
-- This study assessed the safety and immunogenicity of
motavizumab, an investigational anti-RSV MAb, in young children
with a history of prematurity who received two sequential
seasons of the antibody.
RSV Surveillance: Retrospective and Current Data on the Variance in Season Onsets and Offsets (Poster Presentation #719) - Jessie R. Groothuis M.D., MedImmune,
-- Saturday, October 6, 2007; 12:15 - 1:45 p.m. in Poster Halls G-H.
-- A nationwide active surveillance program was established to
evaluate the variability of the RSV season temporally and
geographically in the United States. Laboratory results from a
three-year period were analyzed by month and by geographic
Additional information regarding the IDSA 45TH Annual Meeting can be found at http://www.idsociety.org/Meetingshome.aspx?id=238 .
MedImmune's Commitment to RSV Prevention
MedImmune is a world leader in the development of innovative
therapeutic biologic products to prevent RSV disease. In 1996, MedImmune
launched the first anti-RSV drug, RespiGam(R) (respiratory syncytial virus
immune globulin intravenous (human) (RSV-IGIV)), which was a polyclonal
antibody administered via four-hour intravenous infusion. In 1998,
MedImmune introduced Synagis(R) (palivizumab), which was the first MAb to
receive U.S. Food and Drug Administration (FDA) approval for an infectious
disease. With the development of motavizumab, MedImmune continues to
reinforce its commitment to developing anti-RSV products. In a head-to-head
comparative Phase 3 trial with Synagis, motavizumab met its primary
endpoint of reducing RSV-related hospitalizations in high-risk pe
|SOURCE MedImmune, Inc.|
Copyright©2007 PR Newswire.
All rights reserved